You are here

P&T June 2016


The FDA Has Approved Few, So Lack of Competition Is Keeping Prices High

Biosimilars are a highly anticipated arrival in the pharmacy. However, the undermanned and underfunded FDA struggles to guide, regulate, and approve them.

Health Care & Law

Biosimilars represent a potential savings opportunity for both payers and patients, but how and when the new agents will be accepted and prescribed is uncertain.

Investigators compare the 30-day all-cause readmission rate for 240 patients receiving either rivaroxaban or enoxaparin after total hip or total knee arthroplasty.

Case Report

The authors examine the role that unregulated dietary supplements may have had in a young man who presented with psychotic and homicidal ideations.

Meeting Highlights

The annual meeting of the AACR attracted 19,500 attendees in New Orleans in April. We review key scientific sessions on early clinical research, including immunotherapies.

Pipeline Plus

Psoriasis, a disorder that manifests as a variety of chronic inflammatory skin diseases, affects an estimated 7.4 million Americans. We consider five promising biologic agents poised to enter the psoriasis market for advanced disease by 2019.


Medication Errors

Muting alarms in the post-anesthesia care unit endangers patient safety

Prescription: Washington

CMS Medicare Part B reimbursement plan panned

Approvals, new indications, regulatory activities, and more

Obiltoxaximab injection (Anthim) for anthrax infection; ixekizumab (Taltz) for psoriasis; and reslizumab (Cinqair) for severe asthma

Drug Forecast

Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist for type-2 diabetes